US Patent Issued to ILIAS BIOLOGICS on Nov. 18 for "Use of exosome-based delivery of NF-KappaB inhibitors" (South Korean Inventors)

ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,472,228, issued on Nov. 18, was assigned to ILIAS BIOLOGICS INC. (Daejeon, South Korea).

"Use of exosome-based delivery of NF-KappaB inhibitors" was invented by Chulhee Choi (Daejeon, South Korea), Kyungsun Choi (Daejeon, South Korea) and Jae-Kwang Yoo (Daejeon, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to methods for treating acute kidney injury using exosome containing NF-KappaB inhibitors. The present disclosure relates to methods for treating diseases induced by sepsis using exosome containing NF-KappaB inhibitor. The present disclosure also is related to methods for treating respiratory diseases, such...